Summary
Glucocorticoids (GCs) are steroid hormones, which are essential for life. They are secreted by the adrenal cortex under the control of the hypothalamic-pituitaryadrenal (HPA) axis. Glucocorticoids are essential for the normal function of most organ systems and, in both, excess and deficiency can lead to significant adverse consequences. Adrenal insufficiency (AI) is a rare, life-threatening disorder characterized by insufficient production of corticosteroid hormones. Primary AI is defined by the inability of the adrenal cortex to produce sufficient amounts of glucocorticoids and/or mineralocorticoids despite normal or increased adrenocorticotropin hormone (ACTH). Secondary AI is adrenal hypofunction due to insufficient amount of ACTH produced by the pituitary gland. Conventional treatment of both primary and secondary adrenal insufficiencies involves lifelong glucocorticoid replacement therapy. The role of cortisol deficiency and the impact of hydrocortisone replacement on morbidity and mortality in this patient group are under increasing scrutiny.
Established glucocorticoid replacement regimens do not completely mirror endogenous hormonal production, and their monitoring to ensure optimum therapy is hampered by the lack of reliable biomarkers of hormone sufficiency. A further confounding issue is the tissue-specific regulation of glucocorticoid through the two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD) with research focusing on the role of this prereceptor regulation in the development of adverse metabolic features in patients. This review defines the factors influencing glucocorticoid action in patients with adrenal insufficiency receiving glucocorticoid therapy.
K E Y W O R D S
adrenal insufficiency, cortisol, glucocorticoid metabolism, hypothalamic-pituitary-adrenal axis systemic and inhaled or topical glucocorticoids. 5, 6 HPA axis suppression with glucocorticoid therapy is difficult to predict, hence all patients, even those receiving "low-dose" glucocorticoid therapy (defined as ≤7.5 mg/d prednisone equivalent), 7 must be considered at risk of the development of adrenal insufficiency. All patients with AI require glucocorticoid replacement therapy; however, in contrast to primary AI, patients with SAI or TAI do not require mineralocorticoid replacement, as aldosterone is regulated primarily by the reninangiotensin system, which is independent of the HPA axis. This distinction accounts for the differences in clinical presentation and management between primary and secondary AI.
Cortisol (the main active glucocorticoid in humans) is secreted by the zona fasciculata of the adrenal cortex under the tight control of the HPA axis. Corticotrophin-releasing hormone (CRH) is synthesized and secreted from the hypothalamus, which leads to ACTH (corticotrophin) synthesis and secretion from the pituitary gland, which acts on the zona fasciculata of the adrenal cortex. Classical endocrine feedback loops are in place to control the secretion of glucocorticoids (GC) through a tightly regulated mechanism in the hypothalamus and pituitary gland 8 ( Figure 1 ).
Prior to the discovery of cortisone in 1935 (Kendall's Compound E) and the subsequent production of cortisone as a pharmaceutical for clinical use in 1950, 9 adrenal insufficiency was a fatal condition. Since this discovery, cortisone or subsequently hydrocortisone has been a mainstay of therapy for hormone replacement purposes. In more recent years, there has been much debate as to the most appropriate method of glucocorticoid replacement for both primary and secondary adrenal insufficiency.
In clinical practice, there remains a wide variation in doses used for replacement ranging from 15 to 30 mg (and in some cases even higher doses) of hydrocortisone per day usually in two to three divided doses per day. 10 
| MORTALIT Y AND MORB ID IT Y IN ADRENAL INSUFFICIEN C Y
It has become increasingly evident, that even in patients with treated adrenal insufficiency, there continues to be significant morbidity and reduced life expectancy. Two large registry-based studies of patients with PAI have shown that despite adequate glucocorticoid replacement, the relative risk of death for these patients is more than double that of the background population. There are little data on the effect of glucocorticoid replacement on bone metabolism in patients with SAI. Available data suggest the dose of hydrocortisone is associated with alterations in the bone formation marker osteocalcin (in that reductions in HC dose lead to an increase in osteocalcin). [34] [35] [36] There is growing evidence that patients with adrenal insufficiency have impaired quality of life (QoL), with current replacement regimens failing to restore subjective health status in affected individuals. 37 This reduced subjective health status appears to be irrespective of age, sex, concomitant disease and aetiology of AI.
37
Patients with secondary adrenal insufficiency reported a lower QoL, likely reflecting the contribution of hypopituitarism. 38 Impaired QoL in this patient group may also be contributed to affective and depressive disorders. 39 In addition, current regimens of glucocorticoid replacement therapy fail to replicate the ultradian cortisol rhythm which has recently been shown to be important for human cognition and behaviour. 40 34, 45 ; however, subsequent data showed a poor correlation between clinical assessment and serum cortisol levels. 46 In cases when malabsorption of glucocorticoid therapy is suspected, serum or salivary cortisol monitoring may be useful to guide dosing. The measurement of scalp hair cortisol concentration has been proposed to evaluate the exposure of patients to glucocorticoid excess over longer periods of time than is possible with serum, saliva or urine samples. [47] [48] [49] [50] It is, however, more laborious than cortisol measurements from other biological samples, due to technical aspects of extraction and analysis.
| A SS E SS MENT OF ADEQUAC Y OF G LUCO CORTI COID THER APY
Given the increased mortality and morbidity associated with glucocorticoid use, it is crucial that clinicians who prescribe glucocorticoids understand the factors which dictate glucocorticoid action.
Factors which impact on glucocorticoid action include the following:
1. Oral bioavailability of ingested glucocorticoids 
| B I OAVAIL AB ILIT Y OF OR ALLY IN G E S TED G LUCO CORTI COIDS
Based on historical radioisotope measures of 24-hour cortisol production, the traditional daily dose of hydrocortisone was 30 mg per day split into two doses (frequently, two-thirds in the morning and one-third in the evening). In recent years, it has been reported that the cortisol production rate in normal subjects is less than previously Circadian infusions of hydrocortisone can mimic the normal cortisol rhythm resulting in beneficial effects in patients with Addison's disease and congenital adrenal hyperplasia 58 ; using these infusions, it was also possible to reduce the daily dose of hydrocortisone. 59 Such infusions are, at present, cumbersome and not practical outside of expert centres. However, over the last few years, there has been a push to design orally active delayed or sustained release formulations of hydrocortisone to aid the physiological replacement of hydrocortisone and ultimately improve quality of life and side effect profiles in patients requiring lifelong glucocorticoid replacement. 60 
| HEPATI C ME TABOLIS M (IN PARTI CUL AR THE C Y TO CHROME P450 S YS TEM)
Drug metabolism can be broadly segregated into two categories:
phase I (oxidation, reduction and hydrolysis) and phase II (conjugation 
| CYP3A4 inhibitors
Many drugs can inhibit CYP3A4 function by tight binding to its active site ( 
| CYP3A4 inducers
In their metabolic interaction with CYP3A4 as substrates, a growing number of drugs have the potential to induce (upregulate) hepatic CYP3A4 levels, resulting in accelerated clearance (and reduced efficacy) of concomitantly administered glucocorticoids, which are also CYP3A4 substrates (Table 1) and requires cotreatment with hydrocortisone. The novel use of urinary steroid metabolite analysis steroid has led to the discovery that mitotane inhibits 5α-reductase activity and induces hepatic CYP3A45, which inactivates cortisol to 6b-hydroxycortisol. 69 In addition, mitotane increases CBG. 70 The net effect of increasing cortisol metabolism and reducing free cortisol availability has an important impact on the requirement of gluco- 
| G LUCOCORTICOID ME TABOLIS M
The major route in the metabolism of cortisol comprises the interconversion of cortisol (Kendall's compound F) to cortisone (Kendall's compound E) through the activity of 11β-HSD isozymes or reduction in the C4-5 bond by either 5α-reductase or 5β-reductase to yield 5α-THF (allo-THF) and 5β-THF, respectively 72 ( Figure 2 ). In normal subjects, the 5β metabolites predominate (5βTHF: 5αTHF ratio of 2:1).
THF, allo-THF and tetrahydrocortisone (THE) are rapidly conjugated with glucuronic acid and excreted in the urine. 72 The detailed metabolism of glucocorticoids has been described in detail previously by
Tomlinson et al. 72 These urinary metabolites can be measured using gas chromatography-mass spectrometry (GC/MS) and interpreted as part of a urinary steroid metabolome analysis.
| THE 11 B E TA-HYDROX YS TEROID DEHYDROG ENA S E (11β -H S D) SYS TEM
Within tissues, glucocorticoids are regulated at the prereceptor level by the isozymes of 11β-HSD, which are located in the F I G U R E 2 The major pathways involved in cortisol metabolism (E, cortisone; F, cortisol; Et, etiocholanolone; An, androsterone). THE, tetrahydrocortisone; THF, tetrahydrocortisol endoplasmic reticulum (ER) (Figure 3 
| Genetic polymorphisms of 11β-HSD1
Rare inactivating mutations of the 11HSDB1 gene lead to cortisone reductase deficiency, which presents clinically with increased cortisol clearance and ACTH-driven adrenal hyperandrogenism. 
| THE 5 ALPHA-REDUC TA S E SYS TEM
Glucocorticoids are also metabolized by the A-ring reductases, 5α-and 5β-reductases (5αR and 5βR), via 3α-HSD, to their tetrahydro metabolites, as described above (Figure 2 ). 5α-reduction contributes substantially to the clearance of glucocorticoids. Livingstone et al
showed that mice deficient in 5α reductase type 1 have an eightfold slower clearance of corticosterone. 81 In humans, 5α-reduced glucocorticoid metabolites comprise almost one-half of all urinary cortisol metabolites. 82 Increased excretion of 5α-reduced steroids has been observed in obesity, 82 polycystic ovarian syndrome 83 and nonalcoholic fatty liver disease, 84 while decreased excretion occurs in critical illness. 85 The associated changes in cortisol clearance rate are thought to influence the hypothalamic-pituitary-adrenal axis in these conditions. Tomlinson et al have shown that GC secretion decreased, as did 5α-reductase activity following weight loss, and this may decrease hypothalamic-pituitary-adrenal axis activation and reduce GC metabolite production. 86 In a cohort of patients with SAI, Sherlock et al showed an increase in cortisol tetrahydro metabolites in patients receiving HC compared with patients not F I G U R E 3 Schematic representation of the tissue-specific regulation of glucocorticoid action by the isozymes of 11β-HSD. 11β-HSD, 11β-hydroxysteroid dehydrogenase receiving HC and also that patients receiving the highest dose of HC have an increase in 5α-THF and THF. However, there was no alteration in 5α-THF/THF ratio (marker of 5αR activity). 75 Further studies are required in patients with adrenal insufficiency on glucocorticoid replacement, to clarify the role of the 5α-reductase system in detail.
| IMPAC T OF HYP OPITU ITARIS M AND REPL ACEMENT THER APIE S ON G LUCOCORTICOID ME TABOLIS M
Many patients with SAI due to pituitary disease also have other pituitary hormone deficiencies requiring replacement. The role of the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis on the modulation of corticosteroid metabolism (in particular the 11β-HSD system) has been studied extensively. Weaver et al studied hypopituitary patients with GH deficiency and reported that after 6 months of GH therapy, there was a reduction in urinary cortisol metabolites suggesting either reduced 11β-HSD1 activity or increased 11β-HSD2 activity. 87 Several further in vivo and ex vivo studies have
shown that the GH/IGF-I system (via IGF-I) inhibits 11β-HSD1 action. 88 The phenotype of growth hormone deficiency (GHD) in the context of hypopituitarism may in part be mediated through increased 11β-HSD1 activity 88 as in these GHD patients, the urinary
THF+allo-THF/THE ratio (indicative of increased 11β-HSD1 activity)
is increased by 50% from baseline and reduced after commencing GH therapy 89, 90 without any change in 11β-HSD2 activity. Some authors speculate that a fall in 11β-HSD1 activity with GH therapy may contribute to the reduction in intra-abdominal adipose tissue and the other beneficial effects of GH treatment in GHD. 57 This is clinically relevant, as patients commencing GH therapy may need a slight increase in GC replacement dose. In addition, by accelerating the peripheral metabolism of cortisol, GH therapy may precipitate adrenal insufficiency in susceptible patients with hypopituitarism. 91, 92 Conversely, patients with acromegaly and high IGF-I concentrations have decreased 11β-HSD1 activity; a defect that resolves with appropriate treatment of the GH excess. Sex differences in basal and stress-induced HPA activity have been studied extensively in animals. 94, 95 In patients with AI, the main clinical impact of sex steroid replacement (in particular oestrogen) is its impact on cortisol-binding globulin, which is covered later. In recent years, transdermal oestrogen preparations are being increasingly prescribed in clinical practice. These preparations have less effect on CBG and hence on total serum cortisol levels by reducing hepatic oestrogen exposure. In a cross-sectional observational study in healthy premenopausal woman on oestrogen containing preparations, 100 Qureshi et al observed higher total serum cortisol concentration and higher CBG levels in patients on oral oestrogen administration. Cortisol levels in patients receiving transdermal oestrogen were no different than the control group. Salivary cortisol measurements, a validated marker of free cortisol, were similar in the three groups. 
| CORTISOL-B INDING G LOBULIN

| TIMING/PAT TERN OF DELIVERY OF G LUCO CORTI COIDS
There is evidence that continuous, prolonged, compared with intermittent short exposure to glucocorticoids may have different effects on a number of steroid responsive enzymes. 57 There are also differences in the metabolic impact of glucocorticoids depending on the timing of glucocorticoid administration. 106 At present, the current short-acting hydrocortisone replacement regimens lead to significant peaks and troughs throughout the day.
107
With this in mind, there has been recent interest in the development of modified-release hydrocortisone preparations.
These include a novel once-daily dual-release hydrocortisone tablet, Plenadren, based on an immediate release coating with an extended-release core has been developed to mimic normal cortisol secretion more closely than conventional therapy. 108 The cortisol time-exposure profile achieved using the once-daily dualrelease hydrocortisone treatment has been accompanied by an improvement in several clinical outcomes in patients with primary and secondary adrenal insufficiency. [108] [109] [110] [111] [112] [113] Prospective trials have shown improved cardiovascular risk factors, glucose metabolism and quality of life in comparison with conventional treatment. 114 Interestingly, the daily doses of immediate release hydrocortisone and dual-release hydrocortisone was similar, suggesting that the pattern of hydrocortisone delivery and the circadian cortisol exposure-time profile may therefore be as crucial as the total daily dose in terms of patient outcomes.
Chronocort, another modified-release hydrocortisone preparation, has a multiparticulate formulation and an enteric coat that has a pH trigger of 6.8, allowing small bowel dissolution. 115 This is administered twice daily aiming to mimic the cortisol circadian rhythm and address the physiological overnight ACTH/cortisol increase. Phase II trials have shown it to be effective in controlling androgen excess in adults with congenital adrenal hyperplasia. 
